Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, accompanied by a high estimate of $1025.00 and a low estimate of $840.00.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating and $1,050 price target on Eli Lilly & Company (NYSE:LLY), pointing to the ...

Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $964.46, a high estimate of $1125.00, and a low estimate of $884.00.

The company also raised its full-year outlook, and the stock rallied over 15% since it reported the Q2 numbers. In this note, we discuss Eli Lilly’s stock performance, key takeaways from its ...

Lilly affirmed its full-year revenue guidance, but lowered its profit forecasts. Last quarter , it said it expected 2025 revenue between $58.0 to $61.0 billion, with EPS from $22.05 to $23.55, and ...

Eli Lilly LLY released its first-quarter earnings report on April 30. Here’s Morningstar’s take on Eli Lilly’s earnings and the outlook for its stock. Key Morningstar Metrics for Eli Lilly ...

Eli Lilly (LLY-3.41%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...

Eli Lilly (LLY 0.40%) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival.